Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
2(66.7%)
Phase 4
1(33.3%)
3Total
Phase 1(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT01282060Unknown

Association Between Glycaemic Control and Morbi/Mortality After 5 Years of Follow-up in Type 2 Diabetic Patients

Role: collaborator

NCT00768053Phase 4Completed

Evaluation of EULAR-RAID Score in Rheumatoid Arthritis Patients

Role: collaborator

NCT00349934Phase 1Completed

IMP321 Plus First-line Paclitaxel in Metastatic Breast Carcinoma

Role: collaborator

NCT00351949Phase 1Completed

IMP321 Phase 1 Trial in Metastatic Renal Cell Carcinoma (MRCC)

Role: collaborator

All 4 trials loaded